We Work for Health | Washington

02/25/2026

Remember, government price-setting risks shifting leadership in biotech innovation from the U.S. to other countries.

Read about the possible impacts in this op-ed by Rich Bagger of Drug Wonks:

Republican U.S. Rep. Nicole Malliotakis has consistently raised concerns about the dangers of onerous federal regulations that stifle innovation and economic

02/25/2026

The State of the Union made it clear: Drug pricing is on President Donald J. Trump's mind.

Instead of ensuring low prices make it to patients, Most Favored Nation drug pricing could halt innovation and catapult China to international leadership in biopharma.

02/23/2026

Today, the U.S. is on the cutting edge of the life sciences.

drug pricing risks our global leadership, stalling new discoveries for cancer treatment and other disease areas.

More from We Work for Health:

According to a recent report from the American Cancer Society, the five-year survival rate for cancer in the United States has significantly improved.In the mid-1970s, only half of cancer patients would survive five years or more, now seven in 10 survive.Thanks to technological innovation leading to...

02/20/2026

Over $582 billion has been committed to U.S. infrastructure in the past year.

Track the biopharma investments shaping state economies with We Work for Health’s Biopharma Investment Watch:

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines.

02/18/2026

: Europe is approving more new drugs, but it still trails the U.S.

This is the result of MFN-style pricing. Price controls slow access to innovation. As the U.S. considers MFN, Europe’s experience is a warning.

From We Work for Health:

After several years of steady growth, Europe’s drug regulators are once again increasing the pace of recommended medicines for approval. Last year, European authorities recommended 38 new active substances, delivering a second straight year of elevated output. Even so, Europe continues to lag well...

02/18/2026

This month, Washington Post's editorial board broke down a U.S. biopharma ecosystem that is under threat from the IRA, MFN drug pricing, and intensifying competition with China.

Analysis is clear: Decisive correction is needed.

China is on track to become the world’s pharmaceutical leader if the U.S. keeps blowing its edge.

02/13/2026

: reform efforts focused on transparency passed in on January 30!

Read more from PhRMA about how this impacts patients, hospitals and pharmacists:

02/11/2026

"The US has a long history of bipartisan opposition to corrupt value standards that, in effect, devalue those of us living with disability and our loved ones with disabilities."

Cutting government reimbursement doesn't guarantee patient savings: https://rollcall.com/2026/01/15/congress-should-ban-metric-that-devalues-people-with-disabilities/

02/09/2026

"Innovation is defense. Every discovery made in an American lab and every technological leap forward made within our borders strengthens the economy and increases our global dominance."

MFN would import foreign valuation standards that devalue Americans: https://dcjournal.com/price-controls-undermine-american-national-security/

02/06/2026

"When the United States uses foreign prices or foreign vaccine schedules as a decision rule, it cedes core U.S. health-economic judgments to other governments’ judgements based on their constraints and priorities."

cuts back on U.S. leadership: https://www.americanactionforum.org/weekly-checkup/when-america-copies-instead-of-leads/?utm_source=American+Action+Forum+Emails&utm_campaign=102873124c-EMAIL_CAMPAIGN_2018_08_31_01_22_COPY_01&utm_medium=email&utm_term=0_64783a8335-102873124c-267126413

02/04/2026

"The program increased drug spending of Taft-Hartley plans by 4.7 percent per claim, driving up costs by at least $416 million per year."

Federal reform is needed to ensure the program serves patients as intended: https://www.heraldnet.com/opinion/commentary-stop-abuse-of-federal-program-to-lower-drug-prices/

02/03/2026

"Expanded over-the-counter access would also make the drug market more efficient. When patients buy medicines with their own money, they demand transparent prices."

won't drive down patient costs: https://www.newsmax.com/sallypipes/drug-price-transparency/2026/01/30/id/1244272/